Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Interference01:23

RNA Interference

28.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.0K
RNA Structure01:23

RNA Structure

79.1K
Overview
The basic structure of RNA consists of a five-carbon sugar and one of four nitrogenous bases. Although most RNA is single-stranded, it can form complex secondary and tertiary structures. Such structures play essential roles in the regulation of transcription and translation.
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA): messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three RNA types consist of a...
79.1K
RNA Stability01:53

RNA Stability

35.7K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
35.7K
RNA Splicing01:32

RNA Splicing

60.6K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.6K
RNA Editing02:23

RNA Editing

9.9K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.9K
Eukaryotic RNA Polymerases00:58

Eukaryotic RNA Polymerases

27.1K
RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
27.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Subtypes of Cholangiocarcinoma and their Translational Implications.

Gastroenterology·2026
Same author

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026
Same author

IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers.

JHEP reports : innovation in hepatology·2026
Same author

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience.

Therapeutic advances in medical oncology·2026
Same author

Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?

Expert opinion on biological therapy·2026
Same author

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.

Targeted oncology·2026

Related Experiment Video

Updated: Feb 1, 2026

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data
07:35

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

1.2K

Noncoding RNA in Cholangiocarcinoma.

Massimiliano Salati1,2, Chiara Braconi1,3

  • 1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

Seminars in Liver Disease
|December 12, 2018
PubMed
Summary

Noncoding RNAs (ncRNAs) show promise in treating cholangiocarcinomas (CCAs), a challenging cancer. Further research is needed to overcome obstacles for clinical application of these novel therapies.

More Related Videos

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.3K
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.3K

Related Experiment Videos

Last Updated: Feb 1, 2026

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data
07:35

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

1.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.3K
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cholangiocarcinomas (CCAs) present a significant clinical challenge due to poor prognosis, late diagnosis, and resistance to conventional therapies.
  • Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), are key regulators of gene expression with emerging roles in cancer.
  • The therapeutic potential of ncRNAs in oncology is gaining attention, with early clinical trials underway for miRNA-based treatments.

Purpose of the Study:

  • To review the current evidence on the involvement of ncRNAs in the development and progression of cholangiocarcinomas.
  • To discuss the potential of ncRNAs as diagnostic biomarkers and therapeutic targets for CCA.
  • To highlight the challenges and future directions for implementing ncRNA-based strategies in clinical practice for CCA.

Main Methods:

  • Comprehensive literature review of studies investigating ncRNAs in cholangiocarcinoma.
  • Analysis of recent findings on the functional roles of specific ncRNAs in CCA pathogenesis.
  • Evaluation of preclinical and clinical data related to ncRNA therapeutics in cancer.

Main Results:

  • Accumulating evidence implicates various ncRNAs in the initiation, proliferation, metastasis, and chemoresistance of CCA.
  • Specific ncRNAs have demonstrated potential as biomarkers for early CCA detection and prognosis.
  • Preclinical studies show that modulating ncRNA levels can inhibit CCA growth and sensitize cells to chemotherapy.

Conclusions:

  • ncRNAs represent a promising new avenue for therapeutic intervention in cholangiocarcinoma.
  • Overcoming challenges such as delivery, stability, and off-target effects is crucial for clinical translation.
  • Further research and development are essential to harness the full potential of ncRNAs in combating CCA.